Article ID Journal Published Year Pages File Type
5583983 Seminars in Arthritis and Rheumatism 2017 7 Pages PDF
Abstract
Testing for HLA-B*5801 prior to allopurinol initiation is cost-effective for Asians and African Americans, but not for Caucasians or Hispanics in the United States. Reducing AHS risk by other predictive measures could make HLA-B*5801 testing not cost-effective even among Asians and Blacks.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Anesthesiology and Pain Medicine
Preview
The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States
Authors
, , , , , ,